** Shares of 89Bio ETNB.O down 3.9% at $8.70 premarket after overnight follow-on priced
** Liver disease specialist late Tues sold ~14.7 mln shares, including 3.25 mln pre-funded warrants, at $8.50 for $125 mln gross proceeds
** Offering size boosted from $100 mln, priced at 6.1% discount to last sale
** Co to use net proceeds to fund development of lead candidate, pegozafermin, to treat metabolic dysfunction-associated steatohepatitis (MASH), fatty liver disease formerly known as NASH
** Goldman Sachs, Leerink and Evercore jt bookrunners for offering
** Co has ~106.13 mln shares outstanding for $960 mln market value
** Through Tues, stock off 19% YTD and well below one-year high of $16.63 hit in early Mar
** Co slated to present Phase IIb trial data for pegozafermin at the 75th annual "Liver Meeting" healthcare conf held in San Diego from Nov 15-19
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper.tr.com@reuters.net lance.tupper@tr.com 1-646-279-6380))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。